Raymond James Financial Services Advisors Inc. Sells 1,550 Shares of Moderna, Inc. (NASDAQ:MRNA)

Raymond James Financial Services Advisors Inc. lowered its position in shares of Moderna, Inc. (NASDAQ:MRNAGet Rating) by 3.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 44,180 shares of the company’s stock after selling 1,550 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Moderna were worth $5,224,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Total Clarity Wealth Management Inc. bought a new position in shares of Moderna during the second quarter worth approximately $25,000. Oliver Lagore Vanvalin Investment Group bought a new position in Moderna during the 1st quarter worth $30,000. FinTrust Capital Advisors LLC raised its holdings in Moderna by 754.5% in the 2nd quarter. FinTrust Capital Advisors LLC now owns 188 shares of the company’s stock valued at $31,000 after acquiring an additional 166 shares in the last quarter. Legacy CG LLC bought a new stake in shares of Moderna during the 2nd quarter valued at $34,000. Finally, Castleview Partners LLC grew its holdings in shares of Moderna by 14,182.9% during the 2nd quarter. Castleview Partners LLC now owns 4,999 shares of the company’s stock worth $35,000 after purchasing an additional 4,964 shares in the last quarter. Institutional investors own 63.11% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Cowen dropped their price target on Moderna from $165.00 to $145.00 in a research note on Thursday, October 20th. Argus cut their price objective on shares of Moderna from $180.00 to $150.00 and set a “buy” rating for the company in a research report on Wednesday, September 14th. The Goldman Sachs Group upped their price objective on shares of Moderna from $290.00 to $296.00 and gave the stock a “buy” rating in a research report on Thursday, October 13th. Jefferies Financial Group raised shares of Moderna from a “hold” rating to a “buy” rating and upped their price objective for the stock from $170.00 to $275.00 in a research report on Monday, December 19th. Finally, Deutsche Bank Aktiengesellschaft upped their price objective on shares of Moderna from $185.00 to $225.00 in a research report on Wednesday. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, Moderna has an average rating of “Hold” and a consensus price target of $192.14.

Insider Activity

In other news, Director Noubar Afeyan sold 10,000 shares of the stock in a transaction on Wednesday, October 19th. The stock was sold at an average price of $132.50, for a total value of $1,325,000.00. Following the completion of the transaction, the director now directly owns 2,367,209 shares in the company, valued at approximately $313,655,192.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Stephane Bancel sold 40,000 shares of the stock in a transaction on Wednesday, January 4th. The stock was sold at an average price of $178.11, for a total value of $7,124,400.00. Following the completion of the sale, the chief executive officer now directly owns 5,411,946 shares in the company, valued at $963,921,702.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Noubar Afeyan sold 10,000 shares of the stock in a transaction on Wednesday, October 19th. The shares were sold at an average price of $132.50, for a total value of $1,325,000.00. Following the completion of the sale, the director now owns 2,367,209 shares of the company’s stock, valued at $313,655,192.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 445,899 shares of company stock worth $74,472,586. Insiders own 17.30% of the company’s stock.

Moderna Stock Down 1.6 %

Shares of MRNA opened at $186.64 on Thursday. Moderna, Inc. has a 52 week low of $115.03 and a 52 week high of $228.50. The stock has a market capitalization of $71.70 billion, a price-to-earnings ratio of 6.75 and a beta of 1.71. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.80 and a current ratio of 2.10. The stock has a fifty day moving average of $181.26 and a 200-day moving average of $158.74.

Moderna (NASDAQ:MRNAGet Rating) last announced its quarterly earnings results on Thursday, November 3rd. The company reported $2.53 EPS for the quarter, missing analysts’ consensus estimates of $3.04 by ($0.51). Moderna had a net margin of 55.00% and a return on equity of 70.03%. The firm had revenue of $3.36 billion during the quarter, compared to the consensus estimate of $3.33 billion. As a group, sell-side analysts anticipate that Moderna, Inc. will post 21.44 earnings per share for the current fiscal year.

About Moderna

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

See Also

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.